Inmed pharmaceuticals reports third quarter fiscal 2024 financial results and provides business update

Reported positive preclinical data in both its alzheimer's and dry amd programs closed fiscal q3 with cash position of us$7.9 million vancouver, british columbia--(newsfile corp. - may 14, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced financial results and business update for the third quarter of the fiscal year 2024, which ended march 31, 2024. the company's full financial statements and related md&a for the third quarter ended march 31, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
INM Ratings Summary
INM Quant Ranking